Key Points
- Francis Lo sold 3,125 shares on January 2 at an average price of $16.08 for $50,250, trimming his stake to 315,978 shares (~$5.08M); this follows prior sales of 113,890 shares on Dec. 15 and 4,394 shares on Dec. 22.
- The company reported ($0.15) EPS (beating a ($0.16) estimate) and revenue of $93.97M versus $58.76M, with revenue up 102.4% year‑over‑year, though profitability remains negative.
- ADPT trades around $16.11 with a 52‑week range of $5.97–$20.76 and a $2.46B market cap; analysts have a consensus rating of Moderate Buy and a consensus price target of $17.11, while institutions/hedge funds own about 99.17% of the stock.
Adaptive Biotechnologies Corporation (NASDAQ:ADPT - Get Free Report) insider Francis Lo sold 3,125 shares of Adaptive Biotechnologies stock in a transaction that occurred on Friday, January 2nd. The shares were sold at an average price of $16.08, for a total transaction of $50,250.00. Following the sale, the insider directly owned 315,978 shares in the company, valued at approximately $5,080,926.24. The trade was a 0.98% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.
Francis Lo also recently made the following trade(s):
- On Monday, December 22nd, Francis Lo sold 4,394 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $17.50, for a total value of $76,895.00.
- On Monday, December 15th, Francis Lo sold 113,890 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $15.57, for a total value of $1,773,267.30.
Adaptive Biotechnologies Stock Down 0.4%
ADPT stock opened at $16.11 on Wednesday. Adaptive Biotechnologies Corporation has a 52-week low of $5.97 and a 52-week high of $20.76. The stock has a market cap of $2.46 billion, a price-to-earnings ratio of -29.83 and a beta of 2.18. The business has a fifty day moving average of $16.50 and a two-hundred day moving average of $14.22.
Adaptive Biotechnologies (NASDAQ:ADPT - Get Free Report) last released its quarterly earnings results on Wednesday, November 5th. The company reported ($0.15) earnings per share for the quarter, topping analysts' consensus estimates of ($0.16) by $0.01. The business had revenue of $93.97 million during the quarter, compared to analysts' expectations of $58.76 million. Adaptive Biotechnologies had a negative return on equity of 58.40% and a negative net margin of 31.50%.The company's revenue was up 102.4% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.22) EPS. As a group, sell-side analysts anticipate that Adaptive Biotechnologies Corporation will post -0.92 EPS for the current year.
Institutional Investors Weigh In On Adaptive Biotechnologies
Several large investors have recently added to or reduced their stakes in ADPT. Brighton Jones LLC boosted its position in Adaptive Biotechnologies by 3.1% in the 3rd quarter. Brighton Jones LLC now owns 23,301 shares of the company's stock valued at $349,000 after buying an additional 700 shares during the period. Bouvel Investment Partners LLC raised its stake in shares of Adaptive Biotechnologies by 2.2% in the third quarter. Bouvel Investment Partners LLC now owns 42,878 shares of the company's stock valued at $641,000 after acquiring an additional 904 shares in the last quarter. China Universal Asset Management Co. Ltd. boosted its holdings in Adaptive Biotechnologies by 3.1% in the second quarter. China Universal Asset Management Co. Ltd. now owns 30,512 shares of the company's stock valued at $355,000 after purchasing an additional 910 shares during the period. California State Teachers Retirement System grew its stake in Adaptive Biotechnologies by 1.0% during the 2nd quarter. California State Teachers Retirement System now owns 98,321 shares of the company's stock worth $1,145,000 after purchasing an additional 933 shares in the last quarter. Finally, Captrust Financial Advisors grew its stake in Adaptive Biotechnologies by 7.6% during the 2nd quarter. Captrust Financial Advisors now owns 15,762 shares of the company's stock worth $184,000 after purchasing an additional 1,119 shares in the last quarter. 99.17% of the stock is owned by hedge funds and other institutional investors.
Analysts Set New Price Targets
A number of equities research analysts have weighed in on the stock. Weiss Ratings reiterated a "sell (d-)" rating on shares of Adaptive Biotechnologies in a research report on Wednesday, October 8th. Guggenheim started coverage on shares of Adaptive Biotechnologies in a research report on Tuesday, September 30th. They set a "buy" rating and a $20.00 price objective for the company. Morgan Stanley started coverage on shares of Adaptive Biotechnologies in a report on Monday, December 1st. They issued an "equal weight" rating and a $21.00 target price for the company. Piper Sandler boosted their target price on Adaptive Biotechnologies from $15.00 to $20.00 and gave the company an "overweight" rating in a research report on Wednesday, October 15th. Finally, JPMorgan Chase & Co. raised their price target on Adaptive Biotechnologies from $17.00 to $20.00 and gave the stock an "overweight" rating in a research report on Thursday, November 6th. Eight research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $17.11.
View Our Latest Analysis on Adaptive Biotechnologies
About Adaptive Biotechnologies
(
Get Free Report)
Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.
The company's flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
